Philip Morris International Inc
PM · NYSE
PM · NYSE
Philip Morris International is a tobacco and nicotine-products company whose business is discussed in the supplied evidence within the beverages, alcohol and tobacco industry. It makes money by selling consumer products, although the evidence does not provide segment names, product-level revenue contributions or a geographic split. Its customers are consumers purchasing those products through the company’s distribution network. PM reports FY2025 revenue of $40.6 billion and net income of $11.3 billion, compared with $37.9 billion and $7.1 billion, respectively, in FY2024. The company therefore operates at multibillion-dollar global scale, but its current segment mix is not quantified here.
PM rose $12.33, or 6.76%, from $182.53 to $194.86 over the supplied trading sequence. The clearest company-specific catalyst was Philip Morris International’s 8.8% quarterly-dividend increase to $1.60 per share, equivalent to an annualized $6.40, with payment scheduled for October 26 to shareholders of record on October 2. The stock advanced in each listed session, moving from $182.53 on September 4 to $184.73, $185.71, $189.77, $191.06 and finally $194.86 on September 14. Trading volume peaked at 5.32 million shares on September 11 before falling to 2.94 million on September 14. No other company-specific catalyst or material reversal is identified in the supplied evidence.
Philip Morris fell $2.57, or 1.37%, over the reported period, from $187.30 to $184.73. Trading was initially stable, with the stock closing at $187.15 and then rising to $187.94, before declining to $186.17 and $182.53 in the next two sessions. It recovered to $184.73 on the final reported day, although that rebound only partly reversed the earlier drop. Company-specific coverage highlighted FDA clearance and a higher 2026 outlook, including projected adjusted per-share earnings growth of 7.5%-9.5%, but the supplied evidence does not link those developments to particular daily moves. Valuation remained a counterweight, with coverage describing the shares as inexpensive on cash flow but expensive on earnings. No broader market driver is provided.
The stock fell $4.31, or 2.26%, from the supplied starting close of $190.48 to $186.17. There was no company-specific announcement in the supplied evidence to explain the decline, so trading appears to have reflected broader market or sector positioning rather than a new fundamental catalyst. PM added $1.41 on August 28 before giving back $4.59 on Monday, August 31. It then edged lower on Tuesday, recovered $0.79 on Wednesday, and declined another $1.77 on Thursday. The pattern was therefore a sharp early-week reversal followed by modest stabilization and renewed selling, while the evidence does not identify a specific market-wide driver.
Philip Morris fell 0.54% over the week, from $191.52 to $190.48. The stock rebounded 1.72% on Monday after the prior Friday’s decline, then added another 1.28% on Tuesday and edged higher Wednesday to $194.10. The early-week strength coincided with coverage of Philip Morris’s manufacturing partnership with Altria, which highlighted potential efficiency benefits, and broader optimism around smoke-free products. Thursday’s 1.86% decline gave back most of the preceding gains, but the supplied evidence identifies no company-specific guidance or other catalyst for that reversal. The week therefore ended modestly lower despite support from ZYN’s FDA authorization and favorable IQOS and ZYN commentary.
PM rose $2.61, or 1.38%, from $188.91 to $191.52 over the week. Trading was volatile: the stock fell 3.1% on Monday to $184.52 on its heaviest volume of the period, then recovered across the next three sessions, gaining 1.7% Tuesday, 1.2% Wednesday and 0.8% Thursday. The rebound followed commentary emphasizing Philip Morris’s earnings beat, guidance support and bullish targets, while an ETF-flow alert also identified PM among stocks with changing fund ownership. No dated company-specific announcement was supplied for the week, so the move appears driven mainly by renewed investor support after Monday’s selloff and favorable earnings-related coverage rather than a new fundamental disclosure.
Philip Morris fell $1.41, or 0.75%, from $187.41 to $186.00 over the period. Trading was uneven: the stock slipped to $186.91 on August 4, rebounded to $188.93 on August 5, eased to $188.05 on August 6, and reached $189.57 on August 7 before giving back the entire advance in the final session. The largest move was the 1.9% decline on August 10, on lighter volume of 3.1 million shares. Available evidence does not identify a company-specific announcement or earnings catalyst explaining the weekly reversal. Coverage continued to focus on the $1.2 billion ZYN investment and smoke-free growth, but the market's direct weekly reaction is not documented.
Philip Morris International fell $13.26, or 6.62%, over the provided trading window, from $200.17 on July 28 to $186.91 on August 4. The decline was orderly but persistent: shares slipped to $198.44 on July 29, dropped to $192.00 on July 30, eased to $190.82 on July 31, then fell to $187.41 and $186.91 on August 3-4. The largest move was the $6.44 drop on July 30, followed by a $3.41 decline on August 3. The supplied evidence identifies no company-specific announcement, earnings update, guidance change, analyst action, or quantified market catalyst explaining the selloff, so the week’s driver remains unresolved.
